Materials for Non-Viral Intracellular Delivery of Messenger RNA Therapeutics

Purpose: mRNA therapeutics have broad potential for protein replacement therapy, cancer immunotherapy, and genomic engineering, but effective intracellular delivery remains a major challenge. A chemically diverse suite of delivery materials—originally developed for DNA and siRNA transfection—has recently shown promise for mRNA. This review highlights these materials, their mechanisms of action, routes of administration, dosages, and strategies for optimization specific to mRNA delivery. ---

Hypothesis: No formal testable hypothesis is proposed. The central premise is: if delivery materials originally designed for DNA/siRNA are adapted and optimized for mRNA—accounting for mRNA's larger size, different stability, and cytoplasmic site of action—then efficient and therapeutically relevant non-viral mRNA delivery can be achieved in vivo. ---

Aims: - Highlight classes of materials used for nucleic acid delivery and their application specifically to mRNA. - Focus on mechanisms of action, routes of administration, and dosages for in vivo applications. - Discuss strategies to adapt and optimize materials to address mRNA-specific challenges. - Frame mRNA delivery in the context of the history of DNA and siRNA delivery materials. - Cover naked mRNA, protamine-based systems, lipid and polymer nanoparticles, and hybrid formulations. ---

Delivery system: Payloads: - mRNA (unmodified, base-modified, sequence-optimized, self-amplifying mRNA), siRNA, DNA. Delivery material classes: - Naked mRNA: Direct injection (subcutaneous, intramuscular, intranodal), electroporation, microinjection, gene gun. - Protamine-based: Protamine/mRNA complexes (~300 nm at 2:1 w/w ratio); RNActive® platform. - Lipid-based: - Lipoplexes: DOTAP/DOPE, MegaFectin™, TransIT™, Lipofectamine™. - Lipid nanoparticles (LNPs): DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA, L319, C12-200, cKK-E12, 503O13; formulated with phospholipid, cholesterol, PEG-lipid. - Cationic nanoemulsions (CNE): DOTAP, squalene, sodium trioleate, polysorbate 80. - Polymer-based: - PEI (linear, branched, dendrimer), jetPEI. - PDMAEMA, PLL, chitosan, PBAE, polyaspartamides (PAsp(DET), PEG-PAsp(DET)). - Hybrid formulations: - Lipid/protamine/mRNA (LPR). - Protamine/mRNA complexed with neutral polymer nanoparticles (e.g., PCL). Targeting ligands/functional elements: - GalNAc (for siRNA, not yet mRNA), PEG, apolipoprotein E (ApoE) adsorption, receptor-specific ligands. Base modifications for mRNA: - Pseudouridine (ψ), 5-methylcytidine (5mC); 5′ cap, poly(A) tail, optimized UTRs. ---

Approach: Narrative review of published literature. No primary experimental groups. Model systems discussed include: - In vitro: Various cell lines for transfection and immunogenicity studies. - In vivo: Mice, pigs, rhesus macaques; disease models including anemia, influenza, HIV, cancer, olfactory dysfunction, SP-B deficiency. - Clinical trials: RNActive® (CureVac) in melanoma, NSCLC, prostate cancer. - Disease context: Protein replacement, cancer immunotherapy, infectious disease vaccines, allergy tolerization, genome editing. ---

Key methods: Techniques highlighted across cited studies: - Protein expression (EPO, RFP, luciferase, BDNF, HSV1-tk). - Immune markers (IFN-γ, IL-12, IFN-α). - Hematocrit and reticulocyte counts. - Tumor growth inhibition. - Functional recovery (olfactory dysfunction). - Genome editing (SP-B correction). - siRNA silencing (IC50 determination). - Biodistribution and pharmacokinetics. ---

Key results: - DLinDMA LNP: Delivered 9 kb self-amplifying mRNA at 1–10 µg intramuscularly in mice; provided viral protection comparable to alphavirus vector. - C12-200 LNP optimization: Increased mRNA potency over 7-fold compared to original formulation. - LPR (lipid/protamine/mRNA): Delivered 10 µg HSV1-tk mRNA intravenously; inhibited tumor growth and outperformed DNA treatment in efficacy and toxicity. - PEG-PAsp(DET): Intranasal BDNF mRNA polyplex induced functional recovery in olfactory dysfunction. - siRNA potency evolution: First-generation siRNA-cholesterol conjugate IC50 ~50 mg/kg (2004); LNP with synthetic lipid-like material IC50 ~0.002 mg/kg (2014). - Lipid analogs: DLinDMA IC50 ~1.0 mg/kg; DLin-KC2-DMA ~0.02; DLin-MC3-DMA ~0.005; L319 <0.01. - Cationic nanoemulsion: Self-amplifying mRNA encoding HIV Env was immunogenic in rhesus macaques at 50 µg mRNA dose. - Odd-even effect: Polyaspartamides with odd numbers of aminoethylene repeats exhibited higher mRNA transfection efficacy; opposite effect observed for DNA. ---

Interpretation: The authors conclude that a growing body of literature supports the potential of various delivery materials for mRNA-based therapy. Because of inherent structural differences between mRNA and siRNA, improving mRNA delivery will require further optimization—both reformulating existing materials and developing new ones. The therapeutic potential of mRNA underscores the need for continued development. Several companies are well on the way to commercialization of mRNA therapeutics using non-viral delivery materials, and clinical trials across all phases are actively being pursued. ---

Limitations: - Review, not primary study: No original experimental data; synthesizes published literature. - Naked mRNA limitations: Rapid degradation by ribonucleases, innate immune activation, poor cellular uptake. - No direct conjugation approaches for mRNA yet reported: Unlike siRNA, mRNA is too large, lacks a sense strand for conjugation, and is produced by in vitro transcription with less control over modifications. - Base modifications challenging: Modifications to mRNA bases can alter ribosomal translation; only pseudouridine and 5mC are well-tolerated. - Material-specific limitations: - PEI: relatively cytotoxic and non-degradable. - PLL: high toxicity and poor transfection. - Cationic lipids: toxicity and poor in vivo potency. - Optimal materials may differ between DNA/siRNA and mRNA: Example: odd-even effect for polyaspartamides is opposite for mRNA vs DNA. - Clinical translation still early: Most data are preclinical; long-term safety and efficacy remain to be established. This response is AI-generated, for reference only.